Induced pluripotent stem cell (iPSC) technology has become an important tool for disease modeling. Insufficient data on the variability among iPSC lines derived from a single somatic parental cell line have in practice led to generation and analysis of several, usually three, iPSC sister lines from each parental cell line. We established iPSC lines from a human fibroblast line (HDF-K1) and used transcriptome sequencing to investigate the variation among three sister lines (iPSC-K1A, B, and C). For comparison, we analyzed the transcriptome of an iPSC line (iPSC-K5B) derived from a different fibroblast line (HDF-K5), a human embryonic stem cell (ESC) line (ESC-HS181), as well as the two parental fibroblast lines. All iPSC lines fulfilled stringent criteria for pluripotency. In an unbiased cluster analysis, all stem cell lines (four iPSCs and one ESC) clustered together as opposed to the parental fibroblasts. The transcriptome profiles of the three iPSC sister lines were indistinguishable from each other, and functional pathway analysis did not reveal any significant hits. In contrast, the expression profiles of the ESC line and the iPSC-K5B line were distinct from that of the sister lines iPSC-K1A, B, and C. Differentiation to embryoid bodies and subsequent analysis of germ layer markers in the five stem cell clones confirmed that the distribution of their expression profiles was retained. Taken together, our observations stress the importance of using iPSCs of different parental origin rather than several sister iPSC lines to distinguish disease-associated mechanisms from genetic background effects in disease modeling.
Get full access to this article
View all access options for this article.
References
1.
AbyzovA., MarianiJ., PalejevD., ZhangY., HaneyM.S., TomasiniL., FerrandinoA.F., Rosenberg BelmakerL.A., SzekelyA., WilsonM., KocabasA., CalixtoN.E., GrigorenkoE.L., HuttnerA., ChawarskaK., WeissmanS., UrbanA.E., GersteinM., and VaccarinoF.M. (2012). Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature, 492, 438–442.
AndersS., PylP.T., and HuberW. (2015). HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics, 31, 166–169.
4.
BockC., KiskinisE., VerstappenG., GuH., BoultingG., SmithZ.D., ZillerM., CroftG.F., AmorosoM.W., OakleyD.H., GnirkeA., EgganK., and MeissnerA. (2011). Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell, 144, 439–452.
5.
BoueS., ParamonovI., BarreroM.J., and Izpisua BelmonteJ.C. (2010). Analysis of human and mouse reprogramming of somatic cells to induced pluripotent stem cells. What is in the plate?. PloS One, 5, e12664.
6.
BuganimY., FaddahD.A., ChengA.W., ItskovichE., MarkoulakiS., GanzK., KlemmS.L., van OudenaardenA., and JaenischR. (2012). Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell, 150, 1209–1222.
7.
CaoS., LohK., PeiY., ZhangW., and HanJ. (2012). Overcoming barriers to the clinical utilization of iPSCs: Reprogramming efficiency, safety and quality. Protein Cell, 3, 834–845.
8.
ChenH., QianK., DuZ., CaoJ., PetersenA., LiuH., BlackbournL.W.t., HuangC.L., ErrigoA., YinY., LuJ., AyalaM., and ZhangS.C. (2014). Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell, 14, 796–809.
9.
EbertA.D., YuJ., RoseF.F.Jr., MattisV.B., LorsonC.L., ThomsonJ.A., and SvendsenC.N. (2009). Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature, 457, 277–280.
10.
GaspardN., and VanderhaeghenP. (2011). From stem cells to neural networks: Recent advances and perspectives for neurodevelopmental disorders. Dev. Med. Child Neurol., 53, 13–17.
11.
HamadaM., MalureanuL.A., WijshakeT., ZhouW., and van DeursenJ.M. (2012). Reprogramming to pluripotency can conceal somatic cell chromosomal instability. PLoS Genet., 8, e1002913.
12.
HanssonJ., RafieeM.R., ReilandS., PoloJ.M., GehringJ., OkawaS., HuberW., HochedlingerK., and KrijgsveldJ. (2012). Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. Cell Rep., 2, 1579–1592.
13.
HolmS. (2008). Time to reconsider stem cell ethics—the importance of induced pluripotent cells. J. Med. Ethics, 34, 63–64.
14.
InoueH., and YamanakaS. (2011). The use of induced pluripotent stem cells in drug development. Clin. Pharmacol. Ther., 89, 655–661.
LoB., and ParhamL. (2009). Ethical issues in stem cell research. Endocr. Rev., 30, 204–213.
17.
LoveM.I., HuberW., and AndersS. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 550.
18.
LuoW., FriedmanM.S., SheddenK., HankensonK.D., and WoolfP.J. (2009). GAGE: Generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics, 10, 161.
19.
MeisnerL.F., and JohnsonJ.A. (2008). Protocols for cytogenetic studies of human embryonic stem cells. Methods, 45, 133–141.
20.
MillerJ.D., GanatY.M., KishinevskyS., BowmanR.L., LiuB., TuE.Y., MandalP.K., VeraE., ShimJ.W., KriksS., TaldoneT., FusakiN., TomishimaM.J., KraincD., MilnerT.A., RossiD.J., and StuderL. (2013). Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell, 13, 691–705.
MouX., WuY., CaoH., MengQ., WangQ., SunC., HuS., MaY., and ZhangH. (2012). Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome. Stem Cell Res. Ther., 3, 14.
23.
MuraroM.J., KempeH., and VerschureP.J. (2013). Concise review: The dynamics of induced pluripotency and its behavior captured in gene network motifs. Stem Cells, 31, 838–848.
24.
OhnukiM., TakahashiK., and YamanakaS. (2009). Generation and characterization of human induced pluripotent stem cells. Curr. Protoc. Stem Cell Biol. Chapter 4, Unit 4A:2.
25.
PoloJ.M., AnderssenE., WalshR.M., SchwarzB.A., NefzgerC.M., LimS.M., BorkentM., ApostolouE., AlaeiS., CloutierJ., Bar-NurO., CheloufiS., StadtfeldM., FigueroaM.E., RobintonD., NatesanS., MelnickA., ZhuJ., RamaswamyS., and HochedlingerK. (2012). A molecular roadmap of reprogramming somatic cells into iPS cells. Cell, 151, 1617–1632.
26.
PrilutskyD., PalmerN.P., Smedemark-MarguliesN., SchlaegerT.M., MarguliesD.M., and KohaneI.S. (2014). iPSC-derived neurons as a higher-throughput readout for autism: promises and pitfalls. Trends Mol. Med., 20, 91–104.
27.
PruittK.D., TatusovaT., and MaglottD.R. (2007). NCBI reference sequences (RefSeq): A curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res., 35, D61–D65.
28.
ReinhardtP., GlatzaM., HemmerK., TsytsyuraY., ThielC.S., HoingS., MoritzS., PargaJ.A., WagnerL., BruderJ.M., WuG., SchmidB., RopkeA., KlingaufJ., SchwambornJ.C., GasserT., ScholerH.R., and SterneckertJ. (2013). Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling. PloS One, 8, e59252.
29.
RooneyD., and CzepulskiB. (1992). Human Cytogenetics. A Practical Approach. (Oxford).
30.
SmithK.P., LuongM.X., and SteinG.S. (2009). Pluripotency: Toward a gold standard for human ES and iPS cells. J. Cell. Physiol., 220, 21–29.
SommerC.A., StadtfeldM., MurphyG.J., HochedlingerK., KottonD.N., and MostoslavskyG. (2009). Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells, 27, 543–549.
33.
SommerC.A., and MostoslavskyG. (2013). The evolving field of induced pluripotency: Recent progress and future challenges. J. Cell. Physiol., 228, 267–275.
34.
StaerkJ., DawlatyM.M., GaoQ., MaetzelD., HannaJ., SommerC.A., MostoslavskyG., and JaenischR. (2010). Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell, 7, 20–24.
35.
SturnA., QuackenbushJ., and TrajanoskiZ. (2002). Genesis: Cluster analysis of microarray data. Bioinformatics, 18, 207–208.
36.
TakahashiK., TanabeK., OhnukiM., NaritaM., IchisakaT., TomodaK., and YamanakaS. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861–872.
37.
VaskovaE.A., SteklenevaA.E., MedvedevS.P., and ZakianS.M. (2013). “Epigenetic memory” phenomenon in induced pluripotent stem cells. Acta Naturae, 5, 15–21.
38.
VitaleA.M., MatigianN.A., RavishankarS., BelletteB., WoodS.A., WolvetangE.J., and Mackay-SimA. (2012). Variability in the generation of induced pluripotent stem cells: Importance for disease modeling. Stem Cells Transl. Med., 1, 641–650.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
